Ariad slides again as FDA details adverse event reports

|By:, SA News Editor

Ariad Pharmaceuticals (ARIA -15.1%) takes another big hit on the heels of Wednesday's rout.

The FDA posted a drug safety communication on Iclusig today which contained the following rather disconcerting language: "FDA is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood vessels of patients taking ponatinib ... including heart attacks resulting in death, worsening coronary artery disease, stroke, narrowing of large arteries of the brain, severe narrowing of blood vessels in the extremities, and the need for urgent surgical procedures to restore blood flow." (full report)